Asieris 
Welcome,         Profile    Billing    Logout  
 2 Products   0 Diseases  2 Products   3 Trials   22 News 
14 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cysview (hexaminolevulinate) / Photocure
2015-000436-15: Photodynamisk Diagnostik (PDD) ved flexible cystoskopier - et randomiseret studie med fokus på recidiv

Ongoing
4
696
Europe
Hexvix, Powder and solvent for intravesical suspension, Hexvix
Aarhus Universitet, Photocure
Patients with non muscle invasive bladder cancer in their first year after the diagnosis., Examination and follow up in patients with non muscle invasive bladder cancer., Diseases [C] - Cancer [C04]
 
 
2004-002760-16: A randomised Study of “bluelight” hexyl amino levulinic acid (HAL) photodynamic assisted resection of bladder tumours versus conventional “white light” transurethral resection of newly diagnosed bladder tumours comparing rates of tumour recurrence over one year – A phase IV trial

Ongoing
4
312
Europe
Hexvix, Hexvix, Hexvix
Guy\'s and St Thomas\' NHS Foundation Trust
Superficial Bladder Cancer
 
 
TUR_BLUE, NCT06548438: The Impact of PDD During TURB for NMIBC

Not yet recruiting
4
300
NA
Transurethral resection of the bladder performed with PDD tecnique and Hexvix
A.O.U. Città della Salute e della Scienza, Photocure
Bladder Cancer
03/27
09/27
CUT-less, NCT05962541: Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs)

Not yet recruiting
4
327
NA
PDD-TURBT with hexaminolevulinate (Hexvix®), Hexvix®, Power Led Saphira (TM)
University of Roma La Sapienza
Non-muscle-invasive Bladder Cancer, Non-Muscle Invasive Bladder Urothelial Carcinoma, High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
12/27
02/30
NCT05600322: Comparative Study of Hexvix Blue Light Cystoscopy and White Light Cystoscopy in the Detection of Bladder Cancer

Completed
3
158
RoW
Hexaminolevulinate Hydrochloride, Hexvix, Richard Wolf Photodynamic Diagnostic Equipment (PDD) system, System Blue
Photocure, Jiangsu Yahong Meditech Co., Ltd aka Asieris, Richard Wolf GmbH, Tigermed-Jyton Co., Ltd.
Bladder Cancer
07/23
07/23
NCT06525571: Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection

Recruiting
3
200
US
Cysview, Hexyl aminolevulinate (HAL), Karl Storz D-Light C Photodynamic Diagnostic (PDD) system, Cystoscopy equipment to detect Cysview uptake in the bladder tumors
Johns Hopkins University, Photocure ASA
Bladder Cancer
01/27
01/28
NCT02367547 / 2014-002746-50: Superficial Basal Cell Cancer's Photodynamic Therapy: Comparing Three Photosensitizers: HAL and BF-200 ALA Versus MAL

Active, not recruiting
1/2
117
Europe
Hexylaminolevulinate cream, HAL, Hexvix, Photocure, Aminolevulinic Acid Nano Emulsion, Ameluz, Biofrontera, L01XD04, BF-200 ALA, Methylaminolevulinate cream, Metvix, Galderma, L01X D03, MAL
Joint Authority for Päijät-Häme Social and Health Care, Tampere University, University of Jyvaskyla
Neoplasms, Basal Cell, Carcinoma, Basal Cell, Photochemotherapy, Photosensitizing Agents
09/18
12/25
BLCCR, NCT02660645: Blue Light Cystoscopy With Cysview® Registry

Recruiting
N/A
4400
US
Hexaminolevulinate hydrochloride (HCL), Cysview®, Hexvix®, Karl Storz D-Light C Photodynamic Diagnostic (PDD) system
Photocure, Catalyst Pharmaceutical Research
Bladder Cancer
12/28
12/28
Vesique (nitroxoline) / Asieris
ACCRUE, NCT04490993: Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride Alone in Intermediate and High-risk Chemo-refractory Non-muscle Invasive Bladder Cancer (NMIBC) Patients

Active, not recruiting
3
359
RoW
APL-1202 in combination with Epirubicin, Placebo in combination with Epirubicin
Jiangsu Yahong Meditech Co., Ltd aka Asieris
Non-muscle Invasive Bladder Cancer
05/22
05/22
Ascertain, NCT04736394: A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC Patients

Recruiting
3
800
RoW
APL-1202, Epirubicin Hydrochloride
Jiangsu Yahong Meditech Co., Ltd aka Asieris
Non-muscle Invasive Bladder Cancer
03/25
12/25
ANTICIPATE, NCT04813107: A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer

Recruiting
1/2
79
US, RoW
APL-1202 in combination with tislelizumab, Tislelizumab alone
Jiangsu Yahong Meditech Co., Ltd aka Asieris
Muscle Invasive Bladder Cancer
11/23
03/24
NCT06034015: A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers

Not yet recruiting
1
48
RoW
APL-1202 and APL-1501 (Single ascending dose), APL-1202 and APL-1501 (Multiple Ascending dose)
Jiangsu Yahong Meditech Co., Ltd aka Asieris
Bladder Cancer
01/24
02/24
YHGT-APL1501-NHS-103, NCT06435039: A Study of APL-1501 Extended Release Capsules Compared to APL-1202 Immediate Release Tablets in Healthy Volunteers

Terminated
1
12
RoW
APL-1202, APL-1501
Syneos Health, Asieris Pharmaceuticals (AUS) Pty Ltd.
Healthy Volunteers
07/24
07/24
nepicastat (APL-1401) / Asieris
NCT05743010: A Phase 1b Study to Evaluate APL-1401 in Patients With Moderately to Severely Active Ulcerative Colitis

Recruiting
1b
36
US
APL-1401, Nepicastat, SYN117, Placebo
Jiangsu Yahong Meditech Co., Ltd aka Asieris
Ulcerative Colitis
03/25
04/25
ASN-1764 / Asieris
No trials found
ASN-1780 / Asieris
No trials found
APL-1901 / Asieris
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cysview (hexaminolevulinate) / Photocure
2015-000436-15: Photodynamisk Diagnostik (PDD) ved flexible cystoskopier - et randomiseret studie med fokus på recidiv

Ongoing
4
696
Europe
Hexvix, Powder and solvent for intravesical suspension, Hexvix
Aarhus Universitet, Photocure
Patients with non muscle invasive bladder cancer in their first year after the diagnosis., Examination and follow up in patients with non muscle invasive bladder cancer., Diseases [C] - Cancer [C04]
 
 
2004-002760-16: A randomised Study of “bluelight” hexyl amino levulinic acid (HAL) photodynamic assisted resection of bladder tumours versus conventional “white light” transurethral resection of newly diagnosed bladder tumours comparing rates of tumour recurrence over one year – A phase IV trial

Ongoing
4
312
Europe
Hexvix, Hexvix, Hexvix
Guy\'s and St Thomas\' NHS Foundation Trust
Superficial Bladder Cancer
 
 
TUR_BLUE, NCT06548438: The Impact of PDD During TURB for NMIBC

Not yet recruiting
4
300
NA
Transurethral resection of the bladder performed with PDD tecnique and Hexvix
A.O.U. Città della Salute e della Scienza, Photocure
Bladder Cancer
03/27
09/27
CUT-less, NCT05962541: Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs)

Not yet recruiting
4
327
NA
PDD-TURBT with hexaminolevulinate (Hexvix®), Hexvix®, Power Led Saphira (TM)
University of Roma La Sapienza
Non-muscle-invasive Bladder Cancer, Non-Muscle Invasive Bladder Urothelial Carcinoma, High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
12/27
02/30
NCT05600322: Comparative Study of Hexvix Blue Light Cystoscopy and White Light Cystoscopy in the Detection of Bladder Cancer

Completed
3
158
RoW
Hexaminolevulinate Hydrochloride, Hexvix, Richard Wolf Photodynamic Diagnostic Equipment (PDD) system, System Blue
Photocure, Jiangsu Yahong Meditech Co., Ltd aka Asieris, Richard Wolf GmbH, Tigermed-Jyton Co., Ltd.
Bladder Cancer
07/23
07/23
NCT06525571: Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection

Recruiting
3
200
US
Cysview, Hexyl aminolevulinate (HAL), Karl Storz D-Light C Photodynamic Diagnostic (PDD) system, Cystoscopy equipment to detect Cysview uptake in the bladder tumors
Johns Hopkins University, Photocure ASA
Bladder Cancer
01/27
01/28
NCT02367547 / 2014-002746-50: Superficial Basal Cell Cancer's Photodynamic Therapy: Comparing Three Photosensitizers: HAL and BF-200 ALA Versus MAL

Active, not recruiting
1/2
117
Europe
Hexylaminolevulinate cream, HAL, Hexvix, Photocure, Aminolevulinic Acid Nano Emulsion, Ameluz, Biofrontera, L01XD04, BF-200 ALA, Methylaminolevulinate cream, Metvix, Galderma, L01X D03, MAL
Joint Authority for Päijät-Häme Social and Health Care, Tampere University, University of Jyvaskyla
Neoplasms, Basal Cell, Carcinoma, Basal Cell, Photochemotherapy, Photosensitizing Agents
09/18
12/25
BLCCR, NCT02660645: Blue Light Cystoscopy With Cysview® Registry

Recruiting
N/A
4400
US
Hexaminolevulinate hydrochloride (HCL), Cysview®, Hexvix®, Karl Storz D-Light C Photodynamic Diagnostic (PDD) system
Photocure, Catalyst Pharmaceutical Research
Bladder Cancer
12/28
12/28
Vesique (nitroxoline) / Asieris
ACCRUE, NCT04490993: Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride Alone in Intermediate and High-risk Chemo-refractory Non-muscle Invasive Bladder Cancer (NMIBC) Patients

Active, not recruiting
3
359
RoW
APL-1202 in combination with Epirubicin, Placebo in combination with Epirubicin
Jiangsu Yahong Meditech Co., Ltd aka Asieris
Non-muscle Invasive Bladder Cancer
05/22
05/22
Ascertain, NCT04736394: A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC Patients

Recruiting
3
800
RoW
APL-1202, Epirubicin Hydrochloride
Jiangsu Yahong Meditech Co., Ltd aka Asieris
Non-muscle Invasive Bladder Cancer
03/25
12/25
ANTICIPATE, NCT04813107: A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer

Recruiting
1/2
79
US, RoW
APL-1202 in combination with tislelizumab, Tislelizumab alone
Jiangsu Yahong Meditech Co., Ltd aka Asieris
Muscle Invasive Bladder Cancer
11/23
03/24
NCT06034015: A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers

Not yet recruiting
1
48
RoW
APL-1202 and APL-1501 (Single ascending dose), APL-1202 and APL-1501 (Multiple Ascending dose)
Jiangsu Yahong Meditech Co., Ltd aka Asieris
Bladder Cancer
01/24
02/24
YHGT-APL1501-NHS-103, NCT06435039: A Study of APL-1501 Extended Release Capsules Compared to APL-1202 Immediate Release Tablets in Healthy Volunteers

Terminated
1
12
RoW
APL-1202, APL-1501
Syneos Health, Asieris Pharmaceuticals (AUS) Pty Ltd.
Healthy Volunteers
07/24
07/24
nepicastat (APL-1401) / Asieris
NCT05743010: A Phase 1b Study to Evaluate APL-1401 in Patients With Moderately to Severely Active Ulcerative Colitis

Recruiting
1b
36
US
APL-1401, Nepicastat, SYN117, Placebo
Jiangsu Yahong Meditech Co., Ltd aka Asieris
Ulcerative Colitis
03/25
04/25
ASN-1764 / Asieris
No trials found
ASN-1780 / Asieris
No trials found
APL-1901 / Asieris
No trials found

Download Options